Pharmacogenomics for Clinical Trials of COVID-19 Medicines: Why Is This Important Now?

Sardas, Semra; Özdemir, Vural

Sardas, Semra; Özdemir, Vural.

Sardas S; Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Istinye University, Istanbul, Turkey.
Özdemir V; OMICS: A Journal of Integrative Biology, New Rochelle, New York, USA.

OMICS ; 25(11): 679-680, 2021 11.

Article in English | MEDLINE | ID: covidwho-1483364

Subject(s)

COVID-19 Drug Treatment; Pandemics; Pharmacogenetics/methods; SARS-CoV-2; Antiviral Agents/therapeutic use; COVID-19/genetics; Clinical Trials as Topic/methods; Drug Repositioning; Humans; Pharmacogenetics/trends; Precision Medicine; Proof of Concept Study

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmacogenetics / Pandemics / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: OMICS Journal subject: Molecular Biology Year: 2021 Document Type: Article Affiliation country: Omi.2021.0176

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google